Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amcenestrant versus physician's choice endocrine monotherapy in ER-positive, HER2-negative advanced breast cancer
2018-004593-98Phase 2Completed
- Sponsor
- Sanofi
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of amcenestrant in breast cancer (2 arms), sponsored by Sanofi. Primary endpoint: Progression-free survival. Started Sep 2019; status: completed.
02
Drugs
amcenestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2018-004593-98.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004593-98.